OBJECTIVE: The cAMP-specific phosphodiesterase-4 (PDE4) gene family has four members (PDE4 A, B, C, and D) and is the target of several potential therapeutic inhibitors. Recently, PDE4A5 has been shown to bind with disrupted in schizophrenia 1 (DISC1), which has been identified as a risk factor for schizophrenia, bipolar disorder, and major depression. We sought to examine whether PDE4A5 expression was altered in cerebella of patients with schizophrenia, bipolar disorder, and major depression. METHODS: We measured protein levels of PDE4A isoforms in cerebella of patients with schizophrenia, bipolar disorder, and major depression versus matched controls using sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting. RESULTS: We observed that specific isoforms of PDE4A were reduced in cerebella of patients with bipolar disorder, whereas there was no change in patients with schizophrenia or major depression. CONCLUSION: Our results are the first to show that PDE4A expression is altered in patients with bipolar disorder and provide potential new therapeutic avenues for treatment of this disorder.
OBJECTIVE: The cAMP-specific phosphodiesterase-4 (PDE4) gene family has four members (PDE4 A, B, C, and D) and is the target of several potential therapeutic inhibitors. Recently, PDE4A5 has been shown to bind with disrupted in schizophrenia 1 (DISC1), which has been identified as a risk factor for schizophrenia, bipolar disorder, and major depression. We sought to examine whether PDE4A5 expression was altered in cerebella of patients with schizophrenia, bipolar disorder, and major depression. METHODS: We measured protein levels of PDE4A isoforms in cerebella of patients with schizophrenia, bipolar disorder, and major depression versus matched controls using sodium dodecyl sulfatepolyacrylamide gel electrophoresis and western blotting. RESULTS: We observed that specific isoforms of PDE4A were reduced in cerebella of patients with bipolar disorder, whereas there was no change in patients with schizophrenia or major depression. CONCLUSION: Our results are the first to show that PDE4A expression is altered in patients with bipolar disorder and provide potential new therapeutic avenues for treatment of this disorder.
Authors: Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel Journal: J Neurosci Date: 2016-08-24 Impact factor: 6.167
Authors: Anthony A Oliva; Yuan Kang; Concepcion Furones; Ofelia F Alonso; Olga Bruno; W Dalton Dietrich; Coleen M Atkins Journal: J Neurochem Date: 2012-11-01 Impact factor: 5.372
Authors: Mandy Johnstone; Alan Maclean; Lien Heyrman; An-Sofie Lenaerts; Annelie Nordin; Lars-Göran Nilsson; Peter De Rijk; Dirk Goossens; Rolf Adolfsson; David M St Clair; Jeremy Hall; Stephen M Lawrie; Andrew M McIntosh; Jurgen Del-Favero; Douglas H R Blackwood; Benjamin S Pickard Journal: Mol Neuropsychiatry Date: 2015-10-07